A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02708641|
Recruitment Status : Completed
First Posted : March 15, 2016
Results First Posted : August 10, 2021
Last Update Posted : August 10, 2021
|Condition or disease||Intervention/treatment||Phase|
|Acute Myeloid Leukemia||Drug: pembrolizumab||Phase 2|
Patients >60 years old with AML often have a dismal prognosis. Even though many of these patients are able to obtain a Complete Response to treatment, relapse occurs in the vast majority of patients. Transplants may reduce relapse rates in this population, but is only feasible in a minority of patients. AML's immunosuppressive microenvironment in general and PD-1/PD-L1 upregulation in particular appears to increase the risk of relapse. Importantly, PD-1 and its ligands are particularly increased after therapy compared to initial diagnosis. As such, PD-1 inhibition with pembrolizumab offers to limit leukemic cell immune escape, thereby allowing the patient's immune system to eradicate the submicroscopic residual disease and reducing relapse rates.
Treatment for this study is 200 mg Q3W as an appropriate dose for the switch to fixed dosing is based on simulations performed using the population PK model of Pembrolizumab showing that the fixed dose of 200 mg every 3 weeks will provide exposures that 1) are optimally consistent with those obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient exposures in the exposure range established in melanoma as associated with maximal efficacy response and 3) will maintain individual patients exposure in the exposure range established in melanoma that are well tolerated and safe.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With Acute Myeloid Leukemia (AML) Who Are Not Transplantation Candidates|
|Actual Study Start Date :||October 4, 2016|
|Actual Primary Completion Date :||June 11, 2020|
|Actual Study Completion Date :||December 2020|
Experimental: AML patients
pembrolizumab 200 mg given IV once every three weeks
200 mg IV given every three weeks
Other Name: Keytruda
- Time to Relapse (TTR) [ Time Frame: Up to 24 months ]Time to recurrence of AML, including only deaths related to recurrence. Relapse of AML is defined as patients reaching remission (bone marrow contains <5% blast cells, blood cell counts return to within normal limits, no signs disease) followed by a return of leukemia cells in the marrow and a decrease in normal blood cells.
- Worst Grade of Adverse Events Experienced (Unrelated to Relatedness to Study Therapy) [ Time Frame: Up to 24 months ]Worst Grade of AE experienced, regardless of relatedness to study therapy, per CTCAE v5.0.
- Worst Grade of Adverse Events Experienced (at Least Probably Related to Treatment) [ Time Frame: Up to 24 months ]Worst Grade of AE experienced, at least probably related to treatment, per CTCAE v5.0.
- Overall Survival (OS) [ Time Frame: Up to 48 months ]The length of time from date of start of treatment that patients are still alive.
- Quantification of Activated T Cells [ Time Frame: Up to 24 months ]Determination of activated T cells level (percentages) in peripheral blood. Increased levels of activated T cells may indicate decreasing disease progression.
- Quantification of Activated NK Cells [ Time Frame: Up to 24 months ]Determination of activated NK cells level (percentages) in peripheral blood. Increased levels of activated T cells may indicate decreasing disease progression.
- Quantification of Regulatory T Cells (Treg) [ Time Frame: Up to 24 months ]Determination of regulatory T cell (Treg) levels (percentages) in peripheral blood. Treg cells are involved in cancer progression by inhibiting anti-cancer immunity. Increased levels of Treg cells may indicate progressing disease.
- Cytokine Expression [ Time Frame: Up to 24 months ]Determination of cytokine expression levels (percentages) in peripheral blood. Cytokine expression is associated with cancer progression, immuno-suppression, and decreased anti-cancer response.
- Granzyme B/Perforin Expression [ Time Frame: Up to 24 months ]
Determination of Granzyme B/perforin expression levels (percentages) in peripheral blood.
Granzyme B/perforin expression is associated with the suppression of cancer progression.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02708641
|United States, Pennsylvania|
|Hillman Cancer Center|
|Pittsburgh, Pennsylvania, United States, 15232|
|Principal Investigator:||Michael Boyiadzis, MD, MHSc||UPMC Hillman Cancer Center|